Riskpilot← Back to searchSign inGet full accessPRO CURE AS
ASActiveOrg 983180949Myklerudveien 144, 1454 FagerstrandVeterinary activities · NACE 7500Est. 20012 employeeswww.procure.as
Revenue 2024
NOK 2M
-16% vs 2023
EBITDA margin
-1.3%
-108% vs 2023
Equity ratio
60.0%
Financial strength
Net profit 2024
NOK 1K
-99% vs 2023
| Revenue | NOK 2M | -16% |
| EBITDA | NOK -27K | -108% |
| Net profit | NOK 1K | -99% |
| Total assets | NOK 925K | -37% |
| Equity | NOK 556K | +0% |
| Employees | 2 | — |
Legal name
PRO CURE AS
Org number
983180949
Legal form
Aksjeselskap
NACE code
7500 · Veterinary activities
Founded
30. mars 2001
Share capital
NOK 100 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg.
Company purpose
Formålet med virksomheten er å drive veterinær virksomhet, og import og salg til både privat- og bedriftskunder av veterinære produkter og -utstyr, samt annet som naturlig faller sammen med dette. I tillegg også kjøp og salg av aksjer, samt alminnelig bedriftsrådgivning, import og salg av andre typer av produkter. Virksomheten har både et btb og btc fokus.
Address
Myklerudveien 144, 1454 Fagerstrand
Website
www.procure.as
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1 488 | 2 081 | 2 499 | 2 365 | 1 976 |
| Staff expenses | −430 | −947 | −1 278 | −1 224 | −1 314 |
| EBITDA | 201 | 196 | 283 | 320 | −27 |
| Depreciation & amort. | −248 | −158 | −179 | −209 | −38 |
| EBIT | −47 | 38 | 105 | 111 | −64 |
| Net financials | −42 | 29 | −5 | −31 | 50 |
| Profit before tax | −89 | 67 | 100 | 81 | −14 |
| Tax | −0 | −0 | −0 | −106 | −15 |
| Net profit | −89 | 67 | 100 | 187 | 1 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 093 | 1 158 | 1 534 | 1 478 | 925 |
| Equity | 301 | 368 | 468 | 555 | 556 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 792 | 790 | 1 066 | 923 | 370 |
| Total debt | 792 | 790 | 1 066 | 923 | 370 |
EBITDA margin
-1.3%
This company
15.8%
Market median
-108% vs market
20202024
Equity ratio
60.0%
This company
38.2%
Market median
+57% vs market
20202024
Return on equity
0.2%
This company
18.4%
Market median
-99% vs market
20202024
Net profit margin
0.1%
This company
8.1%
Market median
-99% vs market
20202024
Asset turnover
2.14×
This company
1.12×
Market median
+91% vs market
20202024
Debt / equity
0.67×
This company
0.62×
Market median
+8% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KB Chief Executive Officer | Chief Executive Officer | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
PRO CURE AS 
DYREKLINIKKEN NESODDEN ASBoard members of PRO CURE AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kjeld Bagh Christensen | Chief Executive Officer | 0 companies |
| Sibylla Martha Langaker | Chairman | 0 companies |